Wild-type p53 enhances annexin IV gene expression in ovarian clear cell adenocarcinoma

FEBS Journal

Volumn 278, Issue 9, 2011, Pages 1470-1483

  Masuishi, Yusuke ^a   Arakawa, Noriaki ^a   Kawasaki, Hiroshi ^a   Miyagi, Etsuko ^b   Hirahara, Fumiki ^b   Hirano, Hisashi ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

annexin IV; clear cell adenocarcinoma; ovarian cancer; p53; promoter

Indexed keywords

LIPOCORTIN 4; LUCIFERASE; MUTANT PROTEIN; PROTEIN; PROTEIN P53; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; WILD TYPE PROTEIN;

ARTICLE; CANCER CELL; CELL LINE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GENE CONTROL; GENE EXPRESSION REGULATION; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HYPOTHESIS; INTRON; NUCLEOTIDE SEQUENCE; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN MOTIF; REPORTER GENE; TANDEM REPEAT; TRANSCRIPTION INITIATION SITE;

ADENOCARCINOMA, CLEAR CELL; ANNEXIN A4; FEMALE; GENES, P53; HUMANS; OVARIAN NEOPLASMS; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

EID: 79955058635     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2011.08059.x     Document Type: Article

References (44)

1. Bray F, Loos AH, Tognazzo S, &, La Vecchia C, (2005) Ovarian cancer in Europe: cross-sectional trends in incidence and mortality in 28 countries, 1953-2000. Int J Cancer 113, 977-990. (Pubitemid 40096878)
2. Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, Suzuki M, Sato I, &, Taguchi K, (2000) Clinical characteristics of clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 88, 2584-2589. (Pubitemid 30331967)
3. Itamochi H, Kigawa J, Akeshima R, Sato S, Kamazawa S, Takahashi M, Kanamori Y, Suzuki M, Ohwada M, &, Terakawa N, (2002) Mechanisms of cisplatin resistance in clear cell carcinoma of the ovary. Oncology 62, 349-353. (Pubitemid 34914104)
4. Itamochi H, Kigawa J, Sugiyama T, Kikuchi Y, Suzuki M, &, Terakawa N, (2002) Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet Gynecol 100, 281-287. (Pubitemid 34874791)
5. Itamochi H, Kigawa J, &, Terakawa N, (2008) Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci 99, 653-658. (Pubitemid 351448066)
6. Marks JR, Davidoff AM, Kerns BJ, Humphrey PA, Pence JC, Dodge RK, Clarke-Pearson DL, Iglehart JD, Bast RC Jr, &, Berchuck A, (1991) Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 51, 2979-2984.
7. Kohler MF, Marks JR, Wiseman RW, Jacobs IJ, Davidoff AM, Clarke-Pearson DL, Soper JT, Bast RC Jr, &, Berchuck A, (1993) Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst 85, 1513-1519. (Pubitemid 23269187)
8. Ho ES, Lai CR, Hsieh YT, Chen JT, Lin AJ, Hung MH, &, Liu FS, (2001) p53 mutation is infrequent in clear cell carcinoma of the ovary. Gynecol Oncol 80, 189-193.
9. Okuda T, Otsuka J, Sekizawa A, Saito H, Makino R, Kushima M, Farina A, Kuwano Y, &, Okai T, (2003) p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer. Gynecol Oncol 88, 318-325. (Pubitemid 36331984)
10. Saegusa M, Machida BD, &, Okayasu I, (2001) Possible associations among expression of p14(ARF), p16(INK4a), p21(WAF1/CIP1), p27(KIP1), and p53 accumulation and the balance of apoptosis and cell proliferation in ovarian carcinomas. Cancer 92, 1177-1189. (Pubitemid 32861667)
11. Schaner ME, Ross DT, Ciaravino G, Sorlie T, Troyanskaya O, Diehn M, Wang YC, Duran GE, Sikic TL, Caldeira S, et al. (2003) Gene expression patterns in ovarian carcinomas. Mol Biol Cell 14, 4376-4386. (Pubitemid 37444641)
12. Schwartz DR, Kardia SL, Shedden KA, Kuick R, Michailidis G, Taylor JM, Misek DE, Wu R, Zhai Y, Darrah DM, et al. (2002) Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 62, 4722-4729.
13. Morita A, Miyagi E, Yasumitsu H, Kawasaki H, Hirano H, &, Hirahara F, (2006) Proteomic search for potential diagnostic markers and therapeutic targets for ovarian clear cell adenocarcinoma. Proteomics 6, 5880-5890. (Pubitemid 44764024)
14. Zhu Y, Wu R, Sangha N, Yoo C, Cho KR, Shedden KA, Katabuchi H, &, Lubman DM, (2006) Classifications of ovarian cancer tissues by proteomic patterns. Proteomics 6, 5846-5856. (Pubitemid 44764021)
15. Kim A, Enomoto T, Serada S, Ueda Y, Takahashi T, Ripley B, Miyatake T, Fujita M, Lee CM, Morimoto K, et al. (2009) Enhanced expression of annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin. Int J Cancer 125, 2316-2322.
16. Moss SE, &, Morgan RO, (2004) The annexins. Genome Biol 5, 219.
17. Hill WG, Kaetzel MA, Kishore BK, Dedman JR, &, Zeidel ML, (2003) Annexin A4 reduces water and proton permeability of model membranes but does not alter aquaporin 2-mediated water transport in isolated endosomes. J Gen Physiol 121, 413-425. (Pubitemid 36542774)
18. Sohma H, Creutz CE, Gasa S, Ohkawa H, Akino T, &, Kuroki Y, (2001) Differential lipid specificities of the repeated domains of annexin IV. Biochim Biophys Acta 1546, 205-215. (Pubitemid 32217817)
19. Xie W, Kaetzel MA, Bruzik KS, Dedman JR, Shears SB, &, Nelson DJ, (1996) Inositol 3,4,5,6-tetrakisphosphate inhibits the calmodulin-dependent protein kinase II-activated chloride conductance in T84 colonic epithelial cells. J Biol Chem 271, 14092-14097.
20. Han EK, Tahir SK, Cherian SP, Collins N, &, Ng SC, (2000) Modulation of paclitaxel resistance by annexin IV in human cancer cell lines. Br J Cancer 83, 83-88. (Pubitemid 30352721)
21. el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, &, Vogelstein B, (1992) Definition of a consensus binding site for p53. Nat Genet 1, 45-49.
22. Levine AJ, Momand J, &, Finlay CA, (1991) The p53 tumour suppressor gene. Nature 351, 453-456. (Pubitemid 21896613)
23. Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas DP, Saville MK, &, Lane DP, (2005) p53 isoforms can regulate p53 transcriptional activity. Genes Dev 19, 2122-2137. (Pubitemid 41330315)
24. Meek DW, (1998) Multisite phosphorylation and the integration of stress signals at p53. Cell Signal 10, 159-166. (Pubitemid 28156066)
25. Lane DP, (1992) Cancer. p53, guardian of the genome. Nature 358, 15-16.
26. Ryan KM, Phillips AC, &, Vousden KH, (2001) Regulation and function of the p53 tumor suppressor protein. Curr Opin Cell Biol 13, 332-337. (Pubitemid 32429498)
27. Levesque MA, Katsaros D, Yu H, Zola P, Sismondi P, Giardina G, &, Diamandis EP, (1995) Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 75, 1327-1338.
28. Eltabbakh GH, Belinson JL, Kennedy AW, Biscotti CV, Casey G, Tubbs RR, &, Blumenson LE, (1997) p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer. Cancer 80, 892-898. (Pubitemid 27360471)
29. Shimizu M, Nikaido T, Toki T, Shiozawa T, &, Fujii S, (1999) Clear cell carcinoma has an expression pattern of cell cycle regulatory molecules that is unique among ovarian adenocarcinomas. Cancer 85, 669-677. (Pubitemid 29075288)
30. Skomedal H, Kristensen GB, Abeler VM, Borresen-Dale AL, Trope C, &, Holm R, (1997) TP53 protein accumulation and gene mutation in relation to overexpression of MDM2 protein in ovarian borderline tumours and stage I carcinomas. J Pathol 181, 158-165. (Pubitemid 27087279)
31. Zimmermann U, Balabanov S, Giebel J, Teller S, Junker H, Schmoll D, Protzel C, Scharf C, Kleist B, &, Walther R, (2004) Increased expression and altered location of annexin IV in renal clear cell carcinoma: A possible role in tumour dissemination. Cancer Lett 209, 111-118. (Pubitemid 38625750)
32. Hsueh C, Wang H, Gonzalez-Crussi F, Lin JN, Hung IJ, Yang CP, &, Jiang TH, (2002) Infrequent p53 gene mutations and lack of p53 protein expression in clear cell sarcoma of the kidney: immunohistochemical study and mutation analysis of p53 in renal tumors of unfavorable prognosis. Mod Pathol 15, 606-610. (Pubitemid 34666463)
33. Weiss RH, Borowsky AD, Seligson D, Lin PY, Dillard-Telm L, Belldegrun AS, Figlin RA, &, Pantuck AD, (2007) p21 is a prognostic marker for renal cell carcinoma: implications for novel therapeutic approaches. J Urol 177, 63-68.
34. Robinson M, Jiang P, Cui J, Li J, Wang Y, Swaroop M, Madore S, Lawrence TS, &, Sun Y, (2003) Global genechip profiling to identify genes responsive to p53-induced growth arrest and apoptosis in human lung carcinoma cells. Cancer Biol Ther 2, 406-415.
35. Jen KY, &, Cheung VG, (2005) Identification of novel p53 target genes in ionizing radiation response. Cancer Res 65, 7666-7673. (Pubitemid 41297240)
36. Li M, Brooks CL, Wu-Baer F, Chen D, Baer R, &, Gu W, (2003) Mono- versus polyubiquitination: differential control of p53 fate by Mdm2. Science 302, 1972-1975. (Pubitemid 37523506)
37. Leng RP, Lin Y, Ma W, Wu H, Lemmers B, Chung S, Parant JM, Lozano G, Hakem R, &, Benchimol S, (2003) Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 112, 779-791. (Pubitemid 36378882)
38. Dornan D, Wertz I, Shimizu H, Arnott D, Frantz GD, Dowd P, O'Rourke K, Koeppen H, &, Dixit VM, (2004) The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 429, 86-92. (Pubitemid 38620556)
39. Lavarino C, Pilotti S, Oggionni M, Gatti L, Perego P, Bresciani G, Pierotti MA, Scambia G, Ferrandina G, Fagotti A, et al. (2000) p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. J Clin Oncol 18, 3936-3945.
40. Ueno Y, Enomoto T, Otsuki Y, Sugita N, Nakashima R, Yoshino K, Kuragaki C, Ueda Y, Aki T, Ikegami H, et al. (2006) Prognostic significance of p53 mutation in suboptimally resected advanced ovarian carcinoma treated with the combination chemotherapy of paclitaxel and carboplatin. Cancer Lett 241, 289-300. (Pubitemid 44163043)
41. Gorai I, Nakazawa T, Miyagi E, Hirahara F, Nagashima Y, &, Minaguchi H, (1995) Establishment and characterization of two human ovarian clear cell adenocarcinoma lines from metastatic lesions with different properties. Gynecol Oncol 57, 33-46.
42. Yanagibashi T, Gorai I, Nakazawa T, Miyagi E, Hirahara F, Kitamura H, &, Minaguchi H, (1997) Complexity of expression of the intermediate filaments of six new human ovarian carcinoma cell lines: new expression of cytokeratin 20. Br J Cancer 76, 829-835. (Pubitemid 27401931)
43. Zhu LJ, &, Altmann SW, (2005) mRNA and 18S-RNA coapplication-reverse transcription for quantitative gene expression analysis. Anal Biochem 345, 102-109. (Pubitemid 41558200)
44. Kato Y, Arakawa N, Masuishi Y, Kawasaki H, &, Hirano H, (2009) Mutagenesis of longer inserts by the ligation of two PCR fragments amplified with a mutation primer. J Biosci Bioeng 107, 95-97.